Back to Results
First PageMeta Content
Institute of Cancer Research / AstraZeneca / Cancer research / AKT / Pharmaceutical industry / London / Astex / Medicine / Pharmaceutical sciences


Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca Cambridge, UK, 12th April[removed]Astex Therapeutics, the UK-based biotechnology company developing targeted therapies
Add to Reading List

Open Document

File Size: 11,88 KB

Share Result on Facebook

City

Cambridge / /

Company

GlaxoSmithKline / Johnson & Johnson / Cancer Research Technology Limited / Astex Therapeutics Astex / Astex Therapeutics Ltd / The Institute / AstraZeneca / Novartis / /

Continent

Europe / /

Country

United States / United Kingdom / /

/

Event

Business Partnership / FDA Phase / /

Facility

The Institute of Cancer Research / /

IndustryTerm

biotechnology / treatment of a broad range of cancer / pharmaceutical / /

MedicalCondition

cancers / cancer / tumour / advanced solid tumours / /

NaturalFeature

Media Enquiries College Hill / /

Person

Harren Jhoti / Daniel Gooch / Melanie Toyne Sewell / Jeremy Carmichael / Rebecca Skye Dietrich / /

/

Position

Director of Business Development Tel / Chief Executive Officer / /

Product

AZD5363 / /

PublishedMedium

Cancer Research / /

Technology

drug discovery / /

URL

www.astex-therapeutics.com / /

SocialTag